Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAPHYL vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronchodilator via beta-2 adrenergic receptor agonism; increases c AMP, relaxes bronchial smooth muscle.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Maintenance treatment of asthma,Bronchospasm associated with COPD
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is 7–9 hours in adults with normal hepatic function; prolonged to 20–30 hours in hepatic cirrhosis or heart failure. In neonates, half-life may exceed 30 hours due to immature CYP450 enzymes.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP450 (CYP2D6, CYP3A4) and catechol-O-methyltransferase (COMT).
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites. Less than 10% excreted unchanged in urine; approximately 70% recovered in urine as metabolites, 30% in feces.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40% bound to plasma proteins, primarily albumin.
65% bound to albumin
0.45–0.50 L/kg, approximating total body water. Higher Vd (0.6–0.7 L/kg) in premature neonates and patients with hepatic cirrhosis due to reduced protein binding.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 96–100%; oral extended-release: 90–100%; rectal: 80–90%; intramuscular: 100% (but not recommended due to erratic absorption).
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50% and administer once daily. GFR <15 m L/min: contraindicated.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and administer once daily. Child-Pugh Class C: contraindicated.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Children ≥12 years: initiate at 2.5 mg orally twice daily, increase to 5 mg twice daily after one week; maximum 10 mg twice daily. Children 6–11 years: 1.25 mg orally twice daily, increase to 2.5 mg twice daily after one week; maximum 5 mg twice daily. Children <6 years: not established.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Initiate at 2.5 mg orally twice daily, increase to 5 mg twice daily after one week; maximum 10 mg twice daily. Monitor renal function and adjust per renal dosing.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA boxed warning.
No FDA black box warning.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmia, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to active ingredient or excipients,Cardiac arrhythmias (especially tachyarrhythmias)
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid high-fat meals which may slow absorption. Avoid charcoal-broiled foods which can decrease effectiveness. Limit caffeine intake. Grapefruit juice may increase absorption; avoid excessive consumption.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
DURAPHYL (theophylline) is not associated with major congenital malformations in humans; however, third-trimester use may cause transient neonatal tachycardia, irritability, and jitteriness due to transplacental passage. Limited data suggest no increased risk of first-trimester major defects after therapeutic doses, but high doses near term may lead to caffeine-like withdrawal in neonates.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with an estimated M/P ratio of 0.6–0.7. Infant serum levels may reach 10–50% of maternal therapeutic concentrations. Irritability and sleep disturbance have been reported in breastfed infants. Benefit-risk assessment indicates cautious use; consider monitoring infant for signs of theophylline toxicity.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Theophylline clearance may decrease by 20–40% in the third trimester due to reduced hepatic metabolism. Dose reduction of 20–30% is often required to maintain therapeutic levels. Frequent serum concentration monitoring is advised every 2–4 weeks in the third trimester and postpartum, as clearance normalizes within 1–2 weeks, requiring upward dose adjustment.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Duraphyl (theophylline) has a narrow therapeutic index; monitor serum levels to maintain 10-20 mcg/m L. Avoid in patients with seizure disorders unless adequately controlled. Cimetidine, ciprofloxacin, and macrolides increase levels; rifampin and phenytoin decrease levels. Use with caution in hepatic impairment and congestive heart failure.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heartbeat, seizures, or insomnia.,Do not stop suddenly; tapering may be needed to prevent worsening of breathing problems.,Inform your doctor if you start or stop smoking, as smoking affects theophylline levels.,Keep a regular schedule; take at the same times each day with a full glass of water.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAPHYL vs AEROLATE, answered by our medical review team.
DURAPHYL is a Bronchodilator that works by Bronchodilator via beta-2 adrenergic receptor agonism; increases c AMP, relaxes bronchial smooth muscle.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAPHYL and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAPHYL is: 5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAPHYL and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAPHYL is classified as Category C. DURAPHYL (theophylline) is not associated with major congenital malformations in humans; however, third-trimester use may cause transient neonatal tachycardia, irritability, and ji. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.